Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

To be able to take part in this study, you would generally need to be at least 18 years old and have an advanced solid cancer that has been confirmed by a doctor. Your cancer should also be progressing, meaning it's continuing to grow, and you should be considered well enough for study treatment, typically meaning you can perform your daily activities with minimal difficulty. You would also need to have good organ function, including healthy bone marrow, as determined by standard medical tests.

There are also specific requirements depending on which part of the study you might join. For some parts, you might have had a specific type of previous anti-cancer treatment called a PARPi, while for other parts, having had such a treatment would mean you couldn't join. You would also need to provide a sample of your tumour tissue, if possible, for further analysis.

On the other hand, you would not be able to join if you've recently had certain other treatments, such as particular types of chemotherapy or investigational drugs, within a few weeks of starting the study. Other reasons for not being able to join include taking strong medications that interact with the study drug, having had major surgery recently, or needing high doses of steroids. All these rules are in place to ensure your safety during the study and that the results are as clear as possible.

If you decide to take part in this study, you would receive the study drug, AZD5305, which is taken by mouth, either on its own or alongside other anti-cancer medications. You would have regular appointments at the hospital for check-ups, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. These assessments are crucial for the research team to understand the drug's safety and effectiveness. The exact number and frequency of visits, as well as the types of tests, would be explained in detail by the study team, as they can vary depending on which part of the trial you are in. Throughout your participation, you would be closely monitored by a team of doctors and nurses. The total duration of your participation would depend on how your body responds to the treatment and the study's specific design, but it typically involves an initial treatment phase followed by a monitoring period.